Condition

Pancreatic Carcinoma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 26 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials26

Recruiting4

Common interventions25

Lead sponsors shown15

Clinical trials

26 shown

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasNCT07285044 · 2025-12-18

Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaNCT07359586 · 2025-11-01

The Vanguard Study: Testing a New Way to Screen for CancerNCT06995898 · 2025-06-18

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478 · 2024-02-26

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)NCT07650357 · 2026-07-01

NOT_YET_RECRUITING

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic CancersNCT07118176 · 2025-08-01

ACTIVE_NOT_RECRUITING

Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic CancerNCT04870034 · 2024-01-15

Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab DeviceNCT06789224 · 2022-02-15

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of GenomicsNCT04905082 · 2021-12-30

ACTIVE_NOT_RECRUITING

Clinical Outcomes for Offering Genetic Testing in a Tiered ApproachNCT04902144 · 2020-08-03

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer TissuesNCT04147494 · 2019-11-05

ACTIVE_NOT_RECRUITING

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsNCT03849469 · 2019-05-29

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)NCT03752398 · 2019-05-01

Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate CancerNCT03563352 · 2018-08-30

Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family CaregiversNCT03267524 · 2017-11-09

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-PeptideNCT03164486 · 2016-11-01

ACTIVE_NOT_RECRUITING

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid TumorNCT02839954 · 2016-07-01

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced MalignanciesNCT02807844 · 2016-06-29

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyNCT02432963 · 2016-06-14

ACTIVE_NOT_RECRUITING

Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid TumorNCT02587689 · 2015-10-01

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsNCT02009449 · 2013-11-15

Evaluation of 4D-contrast Enhanced PET-CT in Tumour Volume DefinitionNCT02285660 · 2011-06-01

Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally InvasiveNCT01262040 · 2010-12-14

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous TherapyNCT00892736 · 2009-04-20

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.NCT00423254 · 2007-02-01

An Expanded Access Program for AM0010 (Pegilodecakin)NCT03554434

NO_LONGER_AVAILABLE

Common interventions

Mapped drugs appearing in these trials

Shared trial participation only; not evidence of efficacy or approval.

binimetinib1 capecitabine1 nivolumab1 paclitaxel1 palbociclib1 pazopanib1 pembrolizumab1

Leading sponsors

City of Hope Medical Center 3 Eli Lilly and Company 2 Jonsson Comprehensive Cancer Center 2 National Cancer Institute (NCI) 2 PersonGen BioTherapeutics (Suzhou) Co., Ltd. 2 Xencor, Inc. 2 Clasp Therapeutics, Inc. 1 Daiichi Sankyo 1 Fred Hutchinson Cancer Center 1 Julie L. Sutcliffe, Ph.D 1 Lindis Bloodcare GmbH 1 Mannkind Corporation 1 Mayo Clinic 1 Memorial Sloan Kettering Cancer Center 1 Novartis Pharmaceuticals 1

Trial status mix

COMPLETED10

ACTIVE_NOT_RECRUITING5

RECRUITING4

UNKNOWN3

WITHDRAWN2

NO_LONGER_AVAILABLE1

NOT_YET_RECRUITING1

Phase mix

PHASE111

NA7

PHASE25

EARLY_PHASE13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.